29.07.2024Safety and effectiveness of GPIIb/IIa inhibitors in acute coronary syndrome

Since the introduction of potent P2Y12 inhibitors and newer-generation stents, data on the  glycoprotein IIb/IIIa inhibitor (GPI) use in acute coronary syndrome (ACS) are rare. Recent results from the investigator-initiated multicentre prospective SPUM-ACS study, show that in patients with ACS undergoing percutaneous coronary intervention and receiving potent P2Y12 inhibitors, the use of GPI was associated with reduced risk of MACE and increased risk of major bleedings at 1 year. Although the routine use of GPI is currently not recommended, they might be considered in selected patients.

Florian Wenzl